Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 2
1997 1
1998 2
1999 2
2000 1
2001 1
2003 3
2005 1
2006 3
2007 5
2008 6
2009 5
2010 4
2011 6
2012 7
2013 6
2014 6
2015 6
2016 9
2017 6
2018 5
2019 5
2020 5
2021 12
2022 13
2023 7

Text availability

Article attribute

Article type

Publication date

Search Results

108 results

Results by year

Filters applied: . Clear all
Page 1
Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Salles G, Wierda WG, Izumi R, Munugalavadla V, Patel P, Wang MH, Wong S, Byrd JC. Sharman JP, et al. Among authors: follows g. Lancet. 2020 Apr 18;395(10232):1278-1291. doi: 10.1016/S0140-6736(20)30262-2. Lancet. 2020. PMID: 32305093 Free PMC article. Clinical Trial.
Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, Kamdar M, Munir T, Walewska R, Corbett G, Fogliatto LM, Herishanu Y, Banerji V, Coutre S, Follows G, Walker P, Karlsson K, Ghia P, Janssens A, Cymbalista F, Woyach JA, Ferrant E, Wierda WG, Munugalavadla V, Yu T, Wang MH, Byrd JC. Sharman JP, et al. Among authors: follows g. Leukemia. 2022 Apr;36(4):1171-1175. doi: 10.1038/s41375-021-01485-x. Epub 2022 Jan 1. Leukemia. 2022. PMID: 34974526 Free PMC article. No abstract available.
Massive genomic rearrangement acquired in a single catastrophic event during cancer development.
Stephens PJ, Greenman CD, Fu B, Yang F, Bignell GR, Mudie LJ, Pleasance ED, Lau KW, Beare D, Stebbings LA, McLaren S, Lin ML, McBride DJ, Varela I, Nik-Zainal S, Leroy C, Jia M, Menzies A, Butler AP, Teague JW, Quail MA, Burton J, Swerdlow H, Carter NP, Morsberger LA, Iacobuzio-Donahue C, Follows GA, Green AR, Flanagan AM, Stratton MR, Futreal PA, Campbell PJ. Stephens PJ, et al. Among authors: follows ga. Cell. 2011 Jan 7;144(1):27-40. doi: 10.1016/j.cell.2010.11.055. Cell. 2011. PMID: 21215367 Free PMC article.
Selinexor in patients with relapsed or refractory diffuse large B-cell lymphoma (SADAL): a single-arm, multinational, multicentre, open-label, phase 2 trial.
Kalakonda N, Maerevoet M, Cavallo F, Follows G, Goy A, Vermaat JSP, Casasnovas O, Hamad N, Zijlstra JM, Bakhshi S, Bouabdallah R, Choquet S, Gurion R, Hill B, Jaeger U, Sancho JM, Schuster M, Thieblemont C, De la Cruz F, Egyed M, Mishra S, Offner F, Vassilakopoulos TP, Warzocha K, McCarthy D, Ma X, Corona K, Saint-Martin JR, Chang H, Landesman Y, Joshi A, Wang H, Shah J, Shacham S, Kauffman M, Van Den Neste E, Canales MA. Kalakonda N, et al. Among authors: follows g. Lancet Haematol. 2020 Jul;7(7):e511-e522. doi: 10.1016/S2352-3026(20)30120-4. Lancet Haematol. 2020. PMID: 32589977 Free article. Clinical Trial.
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study.
Munir T, Moreno C, Owen C, Follows G, Benjamini O, Janssens A, Levin MD, Osterborg A, Robak T, Simkovic M, Stevens D, Voloshin S, Vorobyev V, Yagci M, Ysebaert L, Qi K, Qi Q, Parisi L, Srinivasan S, Schuier N, Baeten K, Howes A, Caces DB, Niemann CU, Kater AP. Munir T, et al. Among authors: follows g. J Clin Oncol. 2023 Jul 20;41(21):3689-3699. doi: 10.1200/JCO.22.02283. Epub 2023 Jun 6. J Clin Oncol. 2023. PMID: 37279408 Free PMC article.
Primary testicular lymphoma.
Ahmad SS, Idris SF, Follows GA, Williams MV. Ahmad SS, et al. Among authors: follows ga. Clin Oncol (R Coll Radiol). 2012 Jun;24(5):358-65. doi: 10.1016/j.clon.2012.02.005. Epub 2012 Mar 17. Clin Oncol (R Coll Radiol). 2012. PMID: 22424983 Review.
Platelet satellitism.
Padayatty J, Grigoropoulos N, Gilligan D, Follows GA. Padayatty J, et al. Among authors: follows ga. Eur J Haematol. 2010 Apr;84(4):366. doi: 10.1111/j.1600-0609.2009.01386.x. Epub 2009 Nov 26. Eur J Haematol. 2010. PMID: 20002169 No abstract available.
Hairy cell leukemia - immunotargets and therapies.
Basheer F, Bloxham DM, Scott MA, Follows GA. Basheer F, et al. Among authors: follows ga. Immunotargets Ther. 2014 Jun 24;3:107-20. doi: 10.2147/ITT.S31425. eCollection 2014. Immunotargets Ther. 2014. PMID: 27471703 Free PMC article. Review.
Leukaemia update. Part 1: diagnosis and management.
Grigoropoulos NF, Petter R, Van 't Veer MB, Scott MA, Follows GA. Grigoropoulos NF, et al. Among authors: follows ga. BMJ. 2013 Mar 28;346:f1660. doi: 10.1136/bmj.f1660. BMJ. 2013. PMID: 23538920 Review. No abstract available.
108 results